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LETTERS TO THE EDITORComparing Algorithms for
Genotype Imputation
To the Editor: When the data from a genome-wide associ-
ation study is analyzed, a key question is how to extract the
strongest ‘‘signal’’ of association. Over the last few years,
a class of genotype imputation methods1–3 has become in-
creasingly popular for boosting the signal above that ob-
tained by standard single-SNP analyses.
Here, we deﬁne genotype imputation as the prediction
of genotypes at SNPs that have not been assayed in an
association study. This is typically accomplished by mod-eling allelic correlations among SNPs (many of which
will not have been typed in a given study) in a panel
of known haplotypes, such as the HapMap,4 and extrap-
olating these correlations to a sample of interest through
information from SNPs that have been typed in that
sample.
Sophisticated imputation methods have been shown to
be more powerful than tagging approaches that test only
single SNPs or small haplotypes of SNPs on a genotyping
chip,3 to provide clearer pictures of associated regions
that aid design of replication and ﬁne-mapping studies,5
and to facilitate meta-analysis projects6 by allowing data
sets collected with different genotyping chips to be com-
bined for increased power.Figure 1. Results of Running IMPUTE/SNPTEST and SNPMStat on the Simulated Data Set Provided with the SNPMStat Software
This data set was designed to mimic a real Rheumatoid Arthritis study7 and consists of data at 100 SNPs in 1000 cases and 1000 controls.
Black dots represent tests at genotyped SNPs, and red dots represent tests at imputed SNPs. Test statistics are plotted on the log10
p value scale. Both programs were run under the assumption of an additive model of association. The right-hand plot shows the test
statistics of both methods plotted against each other at all genotyped and imputed SNPs.
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Figure 2. Results of Running IMPUTE/SNPTEST and SNPMStat on a Data Set Simulated with the HAPGEN Program
The data set consists of 500 cases and 500 controls at 300 SNPs on the Affymetrix 500k chip from a region on chromosome 20. Black dots
represent tests at genotyped SNPs, and red dots represent tests at imputed SNPs. Test statistics are plotted on the log10 p value scale.
Both programs were run under the assumption of an additive model of association. The right-hand plot shows the test statistics of both
methods plotted against each other at all genotyped and imputed SNPs.In the February 2008 issue of the Journal, Lin et al.7 pro-
posed a new method of genotype imputation, called
SNPMStat. The main strength of the method is that it
simultaneously ﬁts a model of association and imputes
missing genotypes. Competing methods that impute ge-
notypes without acknowledging phenotypic status for-
mally assume that all of the individuals in a study are no
more related to one another than would be a set of people
sampled at random from a ‘‘population.’’ Near a disease lo-
cus, however, cases are more closely related to each other
than this assumption would imply; consequently, explic-
itly modeling each individual’s disease status could lead
to more accurate imputation and measures of association
strength.
A limiting feature of the proposed method is that it uses
only a small number of SNPs (four at most) to impute each
untyped SNP; this constraint arises from the computa-536 The American Journal of Human Genetics 83, 535–540, Octobetional challenges of ﬁtting a joint model of genotype and
phenotype, and it diminishes the capacity to model com-
plex correlations between SNPs. An additional limitation
is the use of a simple, parametric, multinomial model of
haplotype frequencies: the method’s likelihood-maximiza-
tion process involves an implicit phasing of the SNP geno-
type data, and previous comparisons8 have shown that
this model performs much worse at phasing than do the
models underlying competing imputation approaches.2,3
By contrast, our own method3 (called IMPUTE) and
other methods2 impute genotypes without reference to
phenotype but use more of the ﬂanking SNPs andmore so-
phisticated population-genetics models to predict unob-
served genotypes. These genotypes can then be included
in tests of association (e.g., with our program SNPTEST)
that account for the uncertainty in the predictions and at
the same time condition upon observed covariatesr 10, 2008
Figure 3. Results of Running IMPUTE/SNPTEST and SNPMStat on a Real Data Set in a Region Shown to be Associated with Crohn’s
Disease in the WTCCC Study5
This data set consists of 2938 controls and 1758 cases at 181 of the SNPs on the Affymetrix 500k chip in a 1 Mb region of chromosome 1.
Black dots represent tests at genotyped SNPs, and red dots represent tests at imputed SNPs. Test statistics are plotted on the log10
p value scale. Both programs were run under the assumption of an additive model of association. The right-hand plot shows the test
statistics of both methods plotted against each other at all genotyped and imputed SNPs.(completing what Lin et al. call a ‘‘two-stage’’ procedure,
which contrasts with their ‘‘joint’’ approach).
Many researchers working in this ﬁeld would like to
know which method is most powerful. With regard to the
approaches discussed above, this boils down to whether
a joint model ﬁtted to a small amount of data is more
accurate than a two-stage strategy that makes fuller use
of the genotype data when carrying out imputation.
Intuitively, we can predict that a joint model will prove
most useful when there are large differences between cases
and controls (i.e., risk alleles with strong effects) and that
a two-stage model will fare better if cases and controls
look more similar (this claim is based on the reasonable as-
sumption that the models underlying the two-stage ap-
proaches would impute genotypes more accurately in
a controls-only data set). The conditions under whichThe Amerithe cases and controls are ‘‘different enough’’ for the joint
model to gain an advantage remain unclear, so researchers
are currently looking to simulation studies (and some real
ones) for guidance.
Lin et al. present simulations that they claim extensively
examine the problem of untyped SNPs, and they use these
to suggest that their method is more powerful than exist-
ing two-stage approaches. Unfortunately, their simulations
do not apply the competing approaches in realistic set-
tings, so it is difﬁcult to justify these claims. Speciﬁcally,
all of their simulations involve data sets of ﬁve consecutive
SNPs from chromosome 18 of the CEU HapMap, where
four of the SNPs are used to impute the ﬁfth (whose geno-
types in a simulated case-control set are hidden from the
imputation methods). None of the referenced papers de-
scribe or recommend their use on such small data sets,can Journal of Human Genetics 83, 535–540, October 10, 2008 537
nor are such data sets typical of modern association stud-
ies, so the comparisons might well be biased in favor of
Lin et al.’s joint model.
To investigate this issue, we applied the SNPMStat
method and our own two-stage approach, using the pro-
grams IMPUTE and SNPTEST, to two simulated data sets
and one real data set from the Wellcome Trust Case Con-
trol Consortium (WTCCC) (Figures 1–3). The ﬁrst simu-
lated data set was originally supplied with the SNPMStat
software. This data set was designed to mimic a real
Rheumatoid Arthritis study7 and consists of data at 100
SNPs in 1000 cases and 1000 controls. In the process of
replying to this letter, the authors of SNPMStat found
bugs in SNPMStat, changed the ﬁle formats, and added
new SNPs to the data set. We removed these new SNPs
from the newly formatted ﬁles and reran our analysis
with the new version of the software. For the second data
set, we used the HAPGEN program to simulate 500 cases
and 500 controls at 300 SNPs on the Affymetrix 500k
chip from a region on chromosome 20. The third data
set is a real one from a region shown to be associated
with Crohn’s Disease (CD [MIM 266600]) in the WTCCC
study.5 This data set consists of 2938 controls and 1758
cases at 181 of the SNPs on the Affymetrix 500k chip in
a 1 Mb region of chromosome 1.
Figure 1 depicts a region with a clear signal of associa-
tion. Both methods are able to identify a SNP that is
more strongly associated with disease status than is any
genotyped SNP (illustrating the capacity of imputation
methods to inform subsequent ﬁne-mapping studies),
but IMPUTE/SNPTEST picks out this SNP much more
clearly. Figure 2 shows a region with a much weaker signal
of association: the smallest p value at the genotyped SNPs
does not even reach 103. Here, we see again that both im-
putation methods boost the signal, but with a disparity
between the smallest p values (nearly 106 for IMPUTE/
SNPTEST, as compared to 104 for SNPMStat) that could
easily mean the difference between carrying this region
forward for further scrutiny and losing it among the geno-
mic noise. The comparison in Figure 3 uses real data from
theWTCCC study. As before, although it is clear that either
imputation method can enhance our understanding of
this associated region, our two-stage method ampliﬁes
the signal to a much greater extent—IMPUTE/SNPTEST
achieves a p value over 100 times smaller than the smallest
p value generated by SNPMStat, and our claim about the
strength of this association is supported by external data.9
These three ﬁgures do not amount to a systematic power
comparison, but they are highly suggestive, as shown fur-
ther by the consistently (and appropriately) stronger sig-
nals extracted by IMPUTE/SNPTEST at highly associated,
untyped SNPs throughout these regions (rightmost panels
in Figures 1–3). Thus, on data sets with realistic SNP land-
scapes and disease effect sizes, it appears that muchmore is
gained by the use of advanced population-genetics models
than is lost by failure to model the differences between
cases and controls.538 The American Journal of Human Genetics 83, 535–540, OctobeAs a technical point, we note that power can be com-
pared between two methods only if they both control
their type I error. To assess this for our own method, we
used HAPGEN to simulate a case-control data set consist-
ing of 1000 cases and 1000 controls at all of the SNPs on
the Affymetrix 500K chip on chromosome 1 under the
null hypothesis of no association. We then applied the
IMPUTE/SNPTEST approach to this data set. Figure 4
shows the PP plot based on 50,000 of these SNPs, which
indicates that type I error is controlled very well (as might
be expected from a method that imputes genotypes ‘‘un-
der the null’’).
Finally, it is important in this context to distinguish be-
tween two forms of type I error. The ﬁrst, which we ad-
dress here and Lin et al.7 mention brieﬂy, pertains to
the detection of novel regions of association in the ge-
nome via imputation. The second, which is the focus of
Figure 1 in Lin et al., reﬂects the ability of a method to
separate causal from noncausal associations in the neigh-
borhood of a true risk variant. Both are important issues,
but our methods development has focused primarily on
the ﬁrst of these questions; others have found that
analysis techniques grounded in imputation models sim-
ilar to ours show great promise for ﬁne-mapping applica-
tions.2
In summary, the large and consistent differences shown
in these early results on realistic data sets suggest that
methods that use as much of the available genotype data
as possible might be more powerful than those that ﬁt
a phenotype model using only a subset of the data and
Figure 4. An Evaluation of Type I Error of the IMPUTE/SNPTEST
Approach
HAPGEN was used to simulate a case-control data set consisting of
1000 cases and 1000 controls at all of the SNPs on the Affymetrix
500K chip on chromosome 1 under the null hypothesis of no asso-
ciation. The plot shows the observed log10 p-values at a random
subset of 50,000 of the imputed SNPs versus their expected values
under the null.r 10, 2008
that the simulation studies presented by Lin et al. should,
therefore, be interpreted with caution.
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Human Genetics. All rights reserved.ﬂanking markers around the untyped SNP and select the
subset that provides the best prediction of genotypes at
the untyped SNP. By searching over all possible subsets of
four SNPs among the 20 SNPs closest to each untyped
HapMap SNP, we can typically obtain Rs2 of 1 for more
than 50% of untyped SNPs and Rs2 of > 0.9 for 80% of un-
typed SNPs. It is unclear how much improvement sophis-
ticated population-genetics models can bring.
MH are absolutely right that our simulation studies did
not evaluate the role of sophisticated population-genetics
models. Indeed, we stated this fact in the Discussion of
our article. Our simulation studies were designed to com-
pare the ML and two-stage approaches when the same
set of ﬂanking markers is used. The results showed the efﬁ-
ciency gain of the ML approach due to the use of the phe-
notype information when inferring unobserved genotypes
and the use of retrospective likelihood for reﬂecting case-
control sampling. When applying the ML method to real
data, we always search over a large region around each un-
typed SNP to ﬁnd a set of ﬂanking markers that provides
the best prediction of genotypes for the untyped SNP.
We are intrigued by the comparisons between SNPMStat
and IMPUTE/SNPTEST reported by MH. However, it is dif-
ﬁcult to draw any ﬁrm conclusion from a small number of
selective data sets. The results for the Rheumatoid Arthritis
can Journal of Human Genetics 83, 535–540, October 10, 2008 539
